Skip to main content
Clinical Trials/ISRCTN12811193
ISRCTN12811193
Completed
未知

HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alpha 2a to ongoing tenofovir treatment: an open-label randomized controlled study

King Faisal Specialist Hospital and Research Centre0 sites50 target enrollmentAugust 26, 2016

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
King Faisal Specialist Hospital and Research Centre
Enrollment
50
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 26, 2016
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
King Faisal Specialist Hospital and Research Centre

Eligibility Criteria

Inclusion Criteria

  • 1\. Male or female patients above 18 years of age
  • 2\. Chronic HBV patients receiving Tenofovir 300 mg orally daily for a minimum of 6 months
  • 3\. HBeAg\-positive or HBeAg\-negative patients
  • 4\. HBV DNA \<2000 IU/ml before recruitment
  • 5\. HBsAg should be positive, and HBsAg titer should be measurable from the serum

Exclusion Criteria

  • 1\. Side effects to medications or previous intolerance to Tenofovir or Peg IFN
  • 2\. Impaired renal function with a GFR \<50
  • 3\. Hemoglobin \<12 gm/L in women and \<13 gm/L in men
  • 4\. Severe thrombocytopenia: platelets \<75000
  • 5\. Neutropenia absolute neutrophil count (ANC)\< 1000
  • 6\. Combined infection with HCV, HIV, HDV
  • 7\. Drug\-induced, alcohol related or autoimmune liver disease
  • 8\. Patients with severe depression or other significant psychiatric illness
  • 9\. Previous history of lactic acidosis
  • 10\. Advanced cardiac, pulmonary, renal or neurological diseases

Outcomes

Primary Outcomes

Not specified

Similar Trials